These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15578734)

  • 1. Pharmacokinetics of a novel antiangiogenic agent KR-31831 in rats.
    Kim SJ; Lee HI; Ji HY; Moon Y; Paek IB; Lee S; Yi KY; Yoo SD; Lee HS
    Biopharm Drug Dispos; 2005 Jan; 26(1):21-6. PubMed ID: 15578734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.
    Jeong DW; Kim YH; Kim HH; Ji HY; Yoo SD; Choi WR; Lee SM; Han CK; Lee HS
    Biopharm Drug Dispos; 2007 Mar; 28(2):51-7. PubMed ID: 17163409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of verproside after intravenous and oral administration in rats.
    Park EJ; Lee HS; Oh SR; Lee HK; Lee HS
    Arch Pharm Res; 2009 Apr; 32(4):559-64. PubMed ID: 19407974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dependent pharmacokinetics of a new Na+/H+ exchanger inhibitor KR-33028 in rats.
    Kim YH; Yoo SD; Kim YS; Lee KH; Lee HS
    Biopharm Drug Dispos; 2007 Nov; 28(8):423-9. PubMed ID: 17828714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability, blood partition, and pharmacokinetics of a new reversible proton pump inhibitor, YJA-20379-1.
    Kim SH; Han KS; Choi WS; Chang MS; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):77-84. PubMed ID: 9434317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
    Han KS; Lee MG
    Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a novel histone deacetylase inhibitor, apicidin, in rats.
    Shin BS; Chang HS; Park EH; Yoon CH; Kim HY; Kim J; Ryu JK; Zee OP; Lee KC; Cao D; Yoo SD
    Biopharm Drug Dispos; 2006 Mar; 27(2):69-75. PubMed ID: 16299816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of magnolin in rats.
    Kim NJ; Song WY; Yoo SD; Oh SR; Lee HK; Lee HS
    Arch Pharm Res; 2010 Jun; 33(6):933-8. PubMed ID: 20607499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
    Lee MH; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Yoo SE; Lee MG
    J Pharm Sci; 2003 Jan; 92(1):190-201. PubMed ID: 12486695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma.
    Xu W; Sun J; Zhang TT; Ma B; Cui SM; Chen DW; He ZG
    Acta Pharmacol Sin; 2006 Dec; 27(12):1642-6. PubMed ID: 17112421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone.
    Bae SK; Chung WS; Kim EJ; Rhee JK; Kwon JW; Kim WB; Lee MG
    Biopharm Drug Dispos; 2004 Apr; 25(3):127-35. PubMed ID: 15083501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of L-FMAUS, a new antiviral agent, after intravenous and oral administration to rats: contribution of gastrointestinal first-pass effect to low bioavailability.
    Chung HJ; Lee JH; Woo SJ; Park HK; Koo CH; Lee MG
    Biopharm Drug Dispos; 2007 May; 28(4):187-97. PubMed ID: 17377948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability.
    Yang SH; Lee MG
    Int J Pharm; 2007 Mar; 332(1-2):17-23. PubMed ID: 17157458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
    Harrison A; Betts A; Fenner K; Beaumont K; Edgington A; Roffey S; Davis J; Comby P; Morgan P
    Drug Metab Dispos; 2004 Feb; 32(2):197-204. PubMed ID: 14744941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.